Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Receivables (2016 - 2023)

Historic Change in Receivables for Summit Therapeutics (SMMT) over the last 8 years, with Q3 2023 value amounting to -$3000.0.

  • Summit Therapeutics' Change in Receivables rose 9975.55% to -$3000.0 in Q3 2023 from the same period last year, while for Jun 2024 it was -$3000.0, marking a year-over-year increase of 9824.56%. This contributed to the annual value of -$359000.0 for FY2023, which is 6317.95% up from last year.
  • As of Q3 2023, Summit Therapeutics' Change in Receivables stood at -$3000.0, which was up 9975.55% from -$6000.0 recorded in Q2 2023.
  • Summit Therapeutics' Change in Receivables' 5-year high stood at $8.1 million during Q4 2019, with a 5-year trough of -$3.7 million in Q4 2020.
  • In the last 5 years, Summit Therapeutics' Change in Receivables had a median value of -$3000.0 in 2023 and averaged $415694.0.
  • In the last 5 years, Summit Therapeutics' Change in Receivables surged by 395339.91% in 2020 and then plummeted by 49912.28% in 2022.
  • Summit Therapeutics' Change in Receivables (Quarter) stood at $8.1 million in 2019, then tumbled by 145.46% to -$3.7 million in 2020, then surged by 74.76% to -$932000.0 in 2021, then surged by 251.5% to $1.4 million in 2022, then crashed by 100.21% to -$3000.0 in 2023.
  • Its last three reported values are -$3000.0 in Q3 2023, -$6000.0 for Q2 2023, and -$350000.0 during Q1 2023.